Clinical trial NCT07019597: NESA Neuromodulation Versus Transcutaneous Posterior Tibial Stimulation
Official title: Non-invasive NESA Neuromodulation Versus Transcutaneous Posterior Tibial Nerve Stimulation for the Treatment of Overactive Bladder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bladder Dysfunction
Keywords: overactive bladder
Transcutaneous neuromodulation
Nesa Non-Invasive Neuromodulation
Posterior tibial nerve stimulation
Lead sponsor: University of Las Palmas de Gran Canaria
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 25
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A single-blind, randomised controlled trial was conducted.
Primary purpose: TREATMENT

Brief summary: Introduction: Overactive bladder (OAB) is a common condition characterized by urinary urgency, frequency, and, in some cases, urge incontinence. Non-invasive neuromodulation has emerged as an effective therapeutic option by modulating the neural pathways involved in bladder control. This approach offers a promising alternative for patients who do not respond to conventional treatments.

Objectives: To evaluate the effect of non-invasive NESA neuromodulation compared to posterior tibial stimulation in patients with overactive bladder.

compared to posterior tibial stimulation, with same-day exercises and patient education on quality of life, symptoms, discomfort and sleep.

day of the session and patient education on quality of life, symptoms, discomfort and sleep.

Methods: Twenty-four patients (24 women), aged 38-85 years with overactive bladder will be included in this experimental clinical trial study. Each patient will attend ten sessions two days a week. Patient life quality will be measured using SF-36, sleep quality with the Pittsburgh questionnaire, perception of urinari incontinence (UI) symptoms and patient quality of life with the ICIQ-SF questionnaire. All these variables will be measured before, immediately after the ten sessions and at two months after the end of treatment.

Ethic: The study was approved by the ethics committee of the University of Valencia, and all participants will be given an informed consent form.


Eligibility criteria: Inclusion Criteria:

* Minimum criteria for a primary diagnosis of overactive bladder who have or have not received active/alternative treatments for this pathology.
* Patients with previous pharmacological treatments that have not obtained an adequate clinical response.
* Patients whose cognitive abilities are competent to participate in the study and are able to complete the study questionnaires and have given written consent to participate in the study.
* Without further contraindications for electrotherapy treatment such as serious use of pacemakers, pregnancy, internal bleeding, poor skin condition (ulcerations, wounds...) and/or phobia of electricity.

Exclusion Criteria:

* Presence of urinary fistula.
* Infections in the last 12 months.
* Haematuria during the trial period.
* Pregnancy or plans to become pregnant during the study.
* Pathology of the central or peripheral nervous system (multiple sclerosis, Parkinson's disease, etc.).
* Uncontrolled diabetes.
* Currently treated with Botox injections for the bladder or within the last year.
* Current treatment with interstim or currently implanted interstim device.
* Bladder outlet obstruction.
* Urinary retention.
* Treatment with more than two antidepressants and/or multiple benzodiazepines, as well as antiepileptics.
* Contraindications for electrotherapy treatment.

Primary outcomes:
measure: SF-36 questionnaire
timeFrame: Before treatment, immediately after the treatment is finished and at two months later (follow-up)
Secondary outcomes:
measure: Pittsburgh questionnaire
timeFrame: Sleep quality was assessed before, immediately after and at two months
measure: ICIQ-UI Short Form
timeFrame: ICIQ-SF was assessed before treatment, immediately after the treatment is finished and at two months later (follow-up)
measure: Bladder Control Self-Assessment Questionnaire (B-SAQ)
timeFrame: Before treatment, immediately after the treatment is finished and at two months later (follow-up)
measure: Personal satisfaction of patients
timeFrame: In the follow-up (two month later)
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: University of Valencia
Study officials:
affiliation: University of Valencia
name: Paloma Blasco-Sonora, Physical Therapy
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Valencia
name: Laura FUENTES-APARICIO, PhD. Physical Therapy
role: STUDY_DIRECTOR
affiliation: University of Las Palmas
name: Raquel Medina-Ramírez, PhD. Physical Therapy
role: STUDY_DIRECTOR
References:
citation: Teruel-Hernandez E, Lopez-Pina JA, Souto-Camba S, Baez-Suarez A, Medina-Ramirez R, Gomez-Conesa A. Improving Sleep Quality, Daytime Sleepiness, and Cognitive Function in Patients with Dementia by Therapeutic Exercise and NESA Neuromodulation: A Multicenter Clinical Trial. Int J Environ Res Public Health. 2023 Nov 6;20(21):7027. doi: 10.3390/ijerph20217027.
citation: Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
citation: Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. Toxins (Basel). 2020 Feb 18;12(2):128. doi: 10.3390/toxins12020128.
citation: Przydacz M, Golabek T, Dudek P, Lipinski M, Chlosta P. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020 Nov 13;10(1):19819. doi: 10.1038/s41598-020-76846-0.